Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...
Around five months after its long-serving chief executive Doug Ingram announced he was stepping down, Sarepta Therapeutics ...
Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis. The US regulator has approved icotrokinra under the ...
President Trump's tariffs on goods coming into the US from Europe, China, and Canada could have a profound and damaging impact on the biopharma sector. That's the conclusion of a survey carried out by ...
In November 2025, the UK government introduced the national "Government Strategy and Roadmap" for phasing out animal testing.[1] The US Food and Drug Administration (FDA) has also issued a roadmap and ...
Pharma companies in the UK are being invited to register their new medicines with both the MHRA and NICE at the same time, as part of a push to reduce regulatory review times by three to six months.
In a major shake-up of its UK operations, GSK has started building a brand new R&D centre in Cambridge and will transfer operations there from its current site in Stevenage, Hertfordshire, which has ...
The US federal government has named the next 15 medicines that will be subject to Medicare pricing negotiation and reductions due to come into effect at the start of 2028. The list has been announced ...
Johnson & Johnson has made a $5.5 billion bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close. The settlement offer is dependent on 95% of ...
In a special report (PDF) published to mark the International AIDS Conference underway in Rio de Janeiro, Brazil, the UNAIDS organisation has warned that efforts to end HIV as a public health threat ...
MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...
After three knockbacks by the FDA, Outlook Therapeutics has finally pushed its therapy for wet age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results